Scleroderma gene expression and pathway signatures.
Gene expression studies in scleroderma have shown large and consistent changes in the gene expression of end-target tissues. These changes reflect the lymphocyte infiltration and pathway deregulation potentially linked to disease pathogenesis. Gene expression in scleroderma also reflects the clinical heterogeneity in the disease and can be used to categorize patients. Contained within these gene expression signatures are groups of genes that could serve as biomarkers for clinical end points and disease activity. The use of mechanism-derived gene expression signatures in scleroderma will provide a better understanding of the deregulated pathways contributing to disease pathogenesis.
Sargent
Jennifer L
JL
Department of Genetics, Dartmouth Medical School, 7400 Remsen, Hanover, NH 03755, USA.
Milano
Ausra
A
Connolly
M K
MK
Whitfield
Michael L
ML
D015415:Biomarkers / Q000378:metabolism; D018450:Disease Progression; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D012595:Scleroderma, Systemic / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction / Q000235:genetics*
D015415:Biomarkers